PIRS vs. KZR, CASI, LEXX, EQ, KRON, DARE, CLNN, NBRV, NXTC, and OCUP
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Equillium (EQ), Kronos Bio (KRON), Daré Bioscience (DARE), Clene (CLNN), Nabriva Therapeutics (NBRV), NextCure (NXTC), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Kezar Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Kezar Life Sciences currently has a consensus target price of $11.00, suggesting a potential upside of 1,485.01%. Given Pieris Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kezar Life Sciences is more favorable than Pieris Pharmaceuticals.
In the previous week, Kezar Life Sciences and Kezar Life Sciences both had 2 articles in the media. Pieris Pharmaceuticals' average media sentiment score of 0.94 beat Kezar Life Sciences' score of 0.44 indicating that Kezar Life Sciences is being referred to more favorably in the media.
Pieris Pharmaceuticals has higher revenue and earnings than Kezar Life Sciences. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Pieris Pharmaceuticals received 144 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 61.37% of users gave Pieris Pharmaceuticals an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
Kezar Life Sciences has a net margin of 0.00% compared to Kezar Life Sciences' net margin of -39.71%. Pieris Pharmaceuticals' return on equity of -47.28% beat Kezar Life Sciences' return on equity.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Kezar Life Sciences beats Pieris Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Pieris Pharmaceuticals Competitors List
Related Companies and Tools